Addendum

Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56

Report documents

Indication:

Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction

Result of dossier assessment:

Unchanged after addendum: Added benefit not proven

2023-12-07 A G-BA decision was published.

Project no.: A23-103
Commission: Commission awarded on 24.10.2023 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Heart and circulation
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A23-103

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.